RPL18

Across TCGA pan-cancer cohorts, RPL18 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RPL18’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL18 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL18 is over-expressed in tumor, although a few such as HNSC and BRCA show the opposite, repressed pattern.

KIRC, COAD, and LIHC are the cancer types where RPL18 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL18 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.043	<.001	12	view →
COAD	Female	II,III,IV	+1.338	<.001	10	view →
LIHC	Female	II,III,IV	+1.273	<.001	9	view →
KIRP	All	III,IV	+0.998	<.001	8	view →
CHOL	Male	All	+2.013	<.001	5	view →
LUSC	Male	All	+0.574	<.001	4	view →
THCA	All	All	+0.232	.008	3	view →
READ	All	All	+0.753	.006	2	view →
ESCA	All	All	+0.886	.008	1	view →
HNSC	Female	All	−0.360	.047	1	view →
BRCA	Female	II,III,IV	−0.234	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RPL18–KIRC

Open the KIRC breakdown →